National Institute of Excellence in Health and Social Services

What National Institute of Excellence in Health and Social Services does

INESSS (Institut national d'excellence en santé et en services sociaux) is a Quebec government agency established in 2011 under the Act respecting the Institut national d'excellence en santé et en services sociaux. It evaluates the clinical advantages and costs of health technologies, medications, and social service interventions, formulates recommendations to the Minister for the List of Medications, and develops optimal use guides and clinical decision tools for the Quebec health and social services network. The agency succeeded the Conseil du médicament and the Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS), consolidating Quebec's health technology assessment functions into a single statutory body under the Ministry of Health and Social Services (MSSS).

INESSS's core products are knowledge artifacts and decision-support tools, not commercial technology products. The portfolio includes optimal use guides, clinical algorithms, national medical protocols with associated collective prescriptions, COVID-19 clinical tools, and a digital self-care solutions knowledge base covering diabetes, insomnia, COPD, and mental health conditions. Distribution occurs primarily through the inesss.qc.ca website (Typo3-based) and the INESSS Mobile Application available on Google Play and the App Store, which provides access to optimal use guides, algorithms, national medical protocols, and a COVID-19 section without collecting personal data. All publications, recommendations, guides, and tools are provided free of charge.

INESSS does not operate a commercial revenue model. It is funded through the Quebec government's public budget and serves as a centralized evaluation and guidance body for clinicians, pharmacists, nurses, social workers, healthcare managers, and patients across the province. It cooperates with university-based Health and Social Service Intervention and Technology Assessment Units (UETMISSR), the Réseau Québécois de Diagnostic Moléculaire (RQDM), and a permanent panel of users and caregivers. The agency employs 101–250 staff and is headquartered at 2535 boulevard Laurier, Québec.

Name

National Institute of Excellence in Health and Social Services

Legal name

Institut national d'excellence en santé et en services sociaux

Website

https://inesss.qc.ca

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

INESSS is a Quebec government agency that evaluates health technologies, medications, and social service interventions for the provincial Ministry of Health, producing free clinical guidance, optimal use guides, and decision-support tools for clinicians and patients across Québec.

Ownership category

akta.pro rank

Product category

Health Technology Assessment

NAICS

Social Assistance (624)

SIC

Services-Health Services (8000)

akta.pro industry

PRIMARYHLACAHAC

Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM)

Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics

SECONDARYHLAJAJAM

Data Governance, Standards & Interoperability (ICD, HL7/FHIR, LOINC, SNOMED)

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Statistics, Vital Records & Population Health Analytics

Keywords

• Health technology assessment
• Clinical guidelines development
• Pharmaceutical reimbursement evaluation
• Medical protocol publication
• Healthcare resource optimization

Headquarters

HQ city

Québec

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Distribution channels3 records

Marketing channels5 records

Core offering

INESSS evaluates the clinical advantages, costs, and optimal use of health technologies, medications, and social service interventions for the Quebec healthcare system. It produces evidence-based recommendations, optimal use guides, clinical algorithms, national medical protocols, and digital self-care solutions to support clinical decision-making and efficient resource utilization. The agency also formulates recommendations to the Minister for the provincial List of Medications.

Product overview

INESSS operates as a governmental health technology assessment agency that offers a portfolio of knowledge products and digital tools rather than a single commercial product. The core offerings include the INESSS mobile application (available on Android and iOS) that provides access to clinical tools including Guides d'usage optimal (Optimal Use Guides), Clinical Algorithms, and National Medical Protocols with collective prescriptions. The portfolio also includes the Solutions numériques d'autosoin (Digital Self-Care Solutions) covering diabetes, insomnia, COPD, and mental health conditions. INESSS Express serves as the newsletter for dissemination. These products collectively support clinical decision-making, optimal resource use, and patient involvement in Quebec's health and social services system.

Differentiator

Problem solved

Functional benefit

Brands

• INESSS Guides: Mobile application providing access to guides d'usage optimal (optimal use guides) and clinical support tools for health and social service professionals
• INESSS Express

Products and services

• INESSS Mobile Application

Quantifiable outcome

• More than 80,000 people aged 65+ with major neurocognitive disorders in Quebec community settings were studied for medication use patterns between 2014-2024.
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Health and Social Service Intervention and Technology Assessment Units (UETMISSR)coreStrategic or Co-development PartnerINESSS cooperates with Health and Social service Intervention and Technology Assessment Units in university establishments across Quebec. These units are institutional collaborators involved in the evaluation process of technology, medications, and health and social service interventions.
• Réseau Québécois de Diagnostic Moléculaire (RQDM)coreStrategic or Co-development PartnerThe RQDM, including the Centre Québécois de Génomique Clinique (CQGC), works with INESSS on provincial projects involving technology enhancement, development, and repatriation of next-generation sequencing analyses for molecular diagnostics and personalized medicine.

Scale indicators1 record

Recent moves2 records

Expansion highlights5 records

Direct peers

• Canadian Agency for Drugs and Technologies in Health (CADTH): CADTH is Canada's national HTA agency, performing drug reimbursement reviews and health technology assessments analogous to INESSS. Both bodies produce formulary recommendations and clinical guidance for Canadian jurisdictions, though CADTH operates at the federal/inter-provincial level while INESSS is Quebec-specific.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): IQWiG is Germany's independent federal HTA agency that evaluates the benefit and cost-effectiveness of health technologies and medications. Like INESSS, it produces scientific reports informing national reimbursement decisions through the G-BA.
• Haute Autorité de Santé (HAS): HAS is France's independent public HTA authority that issues clinical guidelines, evaluates drugs and medical devices, and produces recommendations for reimbursement. It closely mirrors INESSS's combination of clinical guidance, drug evaluation, and quality measurement functions.
• Zorginstituut Nederland (ZIN): ZIN is the Netherlands' national HTA body that advises on the basic health insurance package and produces quality standards for care. It shares INESSS's integrated mandate of clinical guideline development, drug reimbursement advice, and quality measurement in a single national body.
• Pharmaceutical Benefits Advisory Committee (PBAC): PBAC is an independent statutory body that advises the Australian Minister for Health on which medicines should be subsidized under the Pharmaceutical Benefits Scheme. It shares INESSS's role of evaluating clinical and cost-effectiveness to inform a publicly administered drug formulary.
• Agenzia Italiana del Farmaco (AIFA): AIFA is Italy's national authority responsible for drug evaluation and reimbursement decisions within the Italian National Health Service. It shares INESSS's combined regulatory and HTA role for pharmaceuticals, though it also functions as the national medicines regulator.

Broad incumbents

• National Institute for Health and Care Excellence (NICE): NICE is the UK's national HTA body producing clinical guidelines, technology appraisals, and drug formulary recommendations. It is the largest and most internationally referenced HTA agency and shares INESSS's core mandate of evaluating clinical and cost-effectiveness of health technologies and interventions.
• Agency for Healthcare Research and Quality (AHRQ): AHRQ is a U.S. federal agency that produces evidence reports, clinical practice guidelines, and quality measurement tools. It overlaps with INESSS's clinical guidance development and quality benchmarking functions but operates at a much larger federal scale with broader research portfolios.

Regional players

• Scottish Medicines Consortium (SMC): SMC provides HTA advice specifically on newly licensed medicines for NHS Scotland. Like INESSS, it serves a sub-national jurisdiction within a larger country and operates within a public-payer system, providing a structurally similar role to INESSS within the UK.

Emerging players

• Institute for Clinical and Economic Review (ICER): ICER is an independent US-based HTA organization producing value-based price benchmarks and clinical effectiveness reports for drugs and other interventions. It overlaps with INESSS's value-assessment mandate but operates as a non-profit funded by payer fees rather than as a government agency.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/INESSS_Qc
• Facebookfacebook.com/INESSSQUEBEC
• LinkedInlinkedin.com/company/institut-national-d%27excellence-en-sant-et-en-services-sociaux-inesss-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute of Excellence in Health and Social Services